EP0873326A1 - Procede de preparation de composes de 2-chlorothiazole - Google Patents

Procede de preparation de composes de 2-chlorothiazole

Info

Publication number
EP0873326A1
EP0873326A1 EP96939236A EP96939236A EP0873326A1 EP 0873326 A1 EP0873326 A1 EP 0873326A1 EP 96939236 A EP96939236 A EP 96939236A EP 96939236 A EP96939236 A EP 96939236A EP 0873326 A1 EP0873326 A1 EP 0873326A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
unsubstituted
preparation
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP96939236A
Other languages
German (de)
English (en)
Other versions
EP0873326B1 (fr
Inventor
Henry Szczepanski
Thomas Göbel
Ottmar Franz HÜTER
Anthony Cornelius O'sulllivan
Marcel Senn
Thomas Rapold
Peter Maienfisch
Thomas Pitterna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Participations AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Ciba Geigy AG, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Publication of EP0873326A1 publication Critical patent/EP0873326A1/fr
Application granted granted Critical
Publication of EP0873326B1 publication Critical patent/EP0873326B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to a process for preparing a compound of the formula
  • X is CH or N
  • Y is N0 2 or CN
  • Z is CHR 3l O, NR 3 or S
  • R and R 2 are either each, independently of the other, hydrogen or unsubstituted or R 4 . substituted alkyl or together a two- or three-membered alkylene bridge or a two- or three-membered alkylene bridge in which one member is replaced by a hetero member selected from the group, consisting of NR 5 , O and S,
  • R 3 is H or unsubstituted or R 4 -substituted alkyl
  • R 4 is an unsubstituted or substituted aryl or heteroaryl group
  • R 5 is H or alkyl, which comprises a) reacting a compound of the formula
  • X, Y, Z, i and R are as defined for the formula I, n is 0, 1 or 2,
  • R 6 is unsubstituted or R 8 -substituted alkyl, unsubstituted or R 8 -substituted alkenyl, unsubstituted or R 8 -substituted alkynyl, cycloalkyl, unsubstituted or substituted aryl, heteroaryl, SR 7 , (alkylene)SH or (alkylene)SR 7 ,
  • R 7 is unsubstituted or R 4 -substituted alkyl, unsubstituted or R 4 -substituted alkenyl, unsub ⁇ stituted or R 4 -substituted alkynyl, cycloalkyl, unsubstituted or substituted aryl, heteroaryl or a group of the formula in which X, Y, Z, Ri and R 2 are as defined for the formula II, and
  • R 8 is an unsubstituted or substituted aryl or heteroaryl group, -COOH, COOM, wherein M is an alkali metal, or -COO-d-C ⁇ -alkyl, with a chlorinating agent, or b1) initially reacting a compound of the formula
  • Carbon-containing groups and compounds each contain, unless defined otherwise, 1 up to and including 8, preferably 1 up to and including 6, in particular 1 up to and including 4, especially 1 or 2 carbon atoms.
  • Halogen is preferably chlorine or bromine.
  • Alkyl - as a group per se and also as a structural element of other groups and compounds, for example alkoxy and alkylthio - is, in each case with due regard to the number of carbon atoms contained in the respective group or compound, either straight-chain, i.e. methyl, ethyl, propyl, butyl, pentyl or hexyl, or branched, for example isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl or isohexyl.
  • Alkenyl and alkynyl are straight-chain or branched and each contain two or preferably one unsaturated carbon-carbon bond(s). The double or triple bonds of these substituents are separated from the remainder of the compound II preferably by at least one saturated carbon atom. Examples include allyl, methallyl, but-2-enyl, but-3-enyl, propargyl, but-2-ynyl and but-3-ynyl.
  • Cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably cyclopropyl.
  • Alkylene - as a group per se and also as a structural element of other groups and compounds, such as (alkylene)SR 7 - is, in each case with due regard to the number of carbon atoms contained in the respective group or compound, either straight-chain, for example -CH 2 CH 2 -, -CH 2 CH 2 CH 2 - or -CH 2 CH 2 CH 2 CH 2 -, or branched, for example -CH(CH 3 )- -CH(C 2 H 5 )-, -C(CH 3 ) 2 - t - CH(CH 3 )CH 2 - or -CH(CH 3 )CH(CH 3 )-, and it can also be methylene.
  • Aryl is phenyl or naphthyl, in particular phenyl.
  • Heteroaryl is a 5- to 7-membered aromatic ring with one to up to three hetero atoms selected from the group consisting of N, O and S. Preference is given to aromatic 5- and 6-membered rings which have a nitrogen atom as hetero atom and which can, if desired, also contain a further hetero atom, preferably nitrogen or sulfur, in particular nitrogen.
  • Substituted aryl and heteroaryl are preferably substitueted with one to three substituents selected from the group consisting of halogen, NO 2 , CN, C ⁇ -C 4 alkyl, C ⁇ -C 4 alkoxy, halogen- CrC alkyl and halogenCrC ⁇ lkoxy.
  • Preferred are unsubstituted or monosubstituted, especially unsubstituted aryl and heteroaryl.
  • Preferred starting materials for preparing the corresponding compounds of the formula I according to the invention are:
  • Ri and R 2 are together a two- or three-membered alkylene bridge with or without a hetero member selected from the group consisting of NR 5 , O and S;
  • R 3 is unsubstituted or R 4 -substituted d-C 4 alkyl, preferably unsubstituted C ⁇ -C 2 alkyl;
  • R 4 is unsubstituted or substituted aryl or heteroaryl, the substituents being selected from the group consisting of halogen, N0 2 , CN, C ⁇ -C alkyl, C 3 -C 6 cycloalkyl, C ⁇ -C 4 alkoxy and d- C alkylthio, preferably unsubstitued aryl;
  • R 6 is unsubstituted or R 8 -substituted d-dalkyl, aryl, heteroaryl, SR 7 , (alkylen)SH or (alkylene)SR 7 , preferably aryl, R 8 -substituted d-C 4 alkyl or SR 7 , in particular R 8 -substituted d-C 2 alkyl or especially aryl;
  • R 7 is unsubstituted or R 4 -substituted alkyl, aryl, heteroaryl or a group of the formula in which X, Y, Z, Ri and R 2 are as defined for the formula II, in particular a group of the formula III;
  • R 8 is aryl or heteroaryl, which are either unstubstituted or substituted, the substituents being selected from the group consisting of halogen, NO 2 , CN, C 1 -C 4 -alkyl, C 3 -C 6 - cycloalkyl, d-d-alkoxy and d-C 4 -alkylthio; in particular unsubstituted aryl.
  • reaction described hereinbefore and hereinafter are carried out in a customary manner, for example in the absence or usually in the presence of a suitable solvent or diluent or a mixture thereof, working as the occasion demands with cooling, at room temperature or with heating, for example at a temperature in the range of from about -80°C to the boiling point of the reaction medium, preferably at about -20°C to about +150°C, and, if necessary, in a closed vessel, at elevated pressure, in an inert-gas atmosphere and/or under anhydrous conditions.
  • a suitable solvent or diluent or a mixture thereof working as the occasion demands with cooling, at room temperature or with heating, for example at a temperature in the range of from about -80°C to the boiling point of the reaction medium, preferably at about -20°C to about +150°C, and, if necessary, in a closed vessel, at elevated pressure, in an inert-gas atmosphere and/or under anhydrous conditions.
  • Suitable halogenating agents are for example elemental chlorine, Javelle water, polysulfur dichloride, sulfur dichloride, phosphorus trichloride, phosphorus pentachloride or mixtures of two or more than two of these compounds, preferably elemental chlorine, Javelle water, sulfur dichloride or a mixture of these two compounds, particularly preferably elemental chlorine of Javelle water.
  • the reaction partners can be reacted with each other without the addition of a solvent or diluent. It may, however, be advantageous to add a solvent or a diluent or a mixture thereof, in which case the amount thereof is not critical.
  • solvents or diluents are: water; alcohols, such as methanol, ethanol, propanol, isopropanol, butanol, ethylene glycol or glycerol; aromatic, aliphatic and alicyclic hydrocarbons and halogenated hydrocarbons, such as benzene, toluene, xylene, mesitylene, tetraline, chlorobenzene, dichlorobenzene, bromobenzene, petroleum ether, hexane, cyclohexane, dichloromethane, trichloromethane, carbon tetrachloride, dichloroethane, trichloroethene or tetrachloroethene; ethers, such as diethyl ether, dipropyl ether, diisopropyl ether, dibutyl ether, tert-butyl methyl ether, ethylene glycol monomethyl ether,
  • the reaction is advantageously carried out at a temperature in the range of from about -20°C to about +180°C, preferably from about 0°C to about +80°C, in many instances in the range between room temperature and the reflux temperature of the reaction mixture.
  • a compound II is reacted at -10°C to 40°C, preferably 0°C, with a chlorinating agent, preferably Javelle water.
  • the reaction is preferably carried out at atmospheric pressure.
  • reaction time is not critical; preference is given to a reaction time of 0.1 to 48 hours, in particular 0.5 to 24 hours.
  • the product is isolated by customary methods, for example filtration, crystallization, distillation or chromatography or any suitable combination of these procedures.
  • Suitable leaving groups Xi in the compounds IV are for example hydroxy, C ⁇ -C 8 alkoxy, halo- C ⁇ -C B alkoxy, CrC 8 alkanoyloxy, mercapto, C ⁇ -C 8 alkylthio, halo-d-C 8 alkylthio, C ⁇ -C 8 alkanesulfonyloxy, halo-d-Coalkanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy and halogen, preferably toluenesulfonyloxy, tri-fluoromethanesulfonyloxy and halogen, in particular halogen.
  • Bases suitable for facilitating the reaction are for example alkali metal or alkaline earth metal hydroxides, hydrides, amides, alkanolates, acetates, carbonates, dialkylamides or alkylsilylamides, alkyiamines, alkylenediamines, free or N-alkylated, saturated or unsaturated cycloalkylamines, basic heterocycles, ammonium hydroxides and also carbocyclic amines.
  • Examples are sodium hydroxide, sodium hydride, sodium amide, sodium methanolate, sodium acetate, sodium carbonate, potassium tert-butanolate, potassium hydroxide, potassium carbonate, potassium hydride, lithium diisopropylamide, potassium bis(trimethylsilyl)amide, calciumhydride, triethylamine, diisopropylethylamine, triethylenediamine, cyclohexylamine, N-cyclohexyl-N.N-dimethylamine, N,N-diethylaniline, pyridine, 4-(N,N-dimethylamino)pyridine, quinuclidine, N-methylmorpholine, benzyltrimethyl- ammonium hydroxide and also 1 ,5-diazabicyclo[5.4.0]undec-5-ene (DBU).
  • DBU 1 ,5-diazabicyclo[5.4.0]undec-5-ene
  • reaction partners can be reacted with each other as such, i.e. without the addition of a solvent or diluent, for example in the melt. In most instances, however, the addition of a solvent or diluent or a mixture thereof is advantageous.
  • solvents or diluents are: water; aromatic, aliphatic and alicyclic hydrocarbons and halogenated hydrocarbons, such as benzene, toluene, xylene, mesityiene, tetraline, chlorobenzene, dichlorobenzene, bromobenzene, petroleum ether, hexane, cyclohexane, dichloromethane, trichloromethane, carbon tetrachloride, dichloroethane, trichloroethene or tetrachloroethene; esters, such as ethyl acetate; ethers, such as diethyl ether, dipropyl ether, diisopropyl ether, dibutyl ether, tert-butyl methyl ether, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol dimethyl ether, dimethoxydie
  • the reaction can also be carried out in a heterogeneous two-phase mixture, for example a mixture of an organic solvent and an aqueous solution of a base, if necessary in the presence of a phase-transfer catalyst such as a crown ether or a tetraalkylammonium salt.
  • a phase-transfer catalyst such as a crown ether or a tetraalkylammonium salt.
  • the reaction is advantageously carried out at a temperature in the range of from about 0°C to about +180°C, preferably from about +10°C to about +80°C, in many instances in the range between room temperature and the reflux temperature of the reaction mixture.
  • a compound IV is reacted at 0°C to 120°C, preferably 20°C to 80°C, in particular 60°C to 80°C, in an amide, preferably N.N-dimethylformamide, with a compound V.
  • the reaction is preferably carried out at atmospheric pressure.
  • reaction time is not critical; preference is given to a reaction time of 0.1 to 48 hours, in particular 0.5 to 24 hours.
  • the product is isolated by customary methods, for example filtration, crystallization, distillation or chromatography or any suitable combination of these procedures.
  • Suitable halogenating agents are for example of the kind stated under variant a).
  • reaction partners can be reacted with each other as such, i.e. without the addition of a solvent or diluent, for example in the melt. In most instances, however, the addition of a solvent or diluent or a mixture thereof is advantageous. Suitable solvents or diluents are for example of the kind stated under variant a).
  • the reaction is advantageously carried out at a temperature in the range of from about -20°C to about +180°C, preferably from about 0°C to about +80 C C, in many instances between room temperature and the reflux temperature of the reaction mixture.
  • a compound II is reacted with a chlorinating agent, preferably elemental chlorine or Javelle water, at -10°C to 40°C, preferably 0°C.
  • a chlorinating agent preferably elemental chlorine or Javelle water
  • the reaction is preferably carried out at atmospheric pressure.
  • reaction time is not critical; preference is given to a reaction time of 0.1 to 48 hours, in particular 0.5 to 24 hours.
  • the product is isolated by customary methods, for example filtration, crystallization, distillation or chromatography or any suitable combination of these procedures.
  • Novel starting materials or intermediates in each case either in their free form or as salts, that are used according to the invention for preparing compounds of the formulae I, II, IV or VII or their salts, respectively, a process for their preparation and their use as starting materials or intermediates for preparing the compounds I, II, IV or VII also form part of the subject-matter of the invention.
  • the compounds II can be prepared for example as described under variant b1).
  • the compounds of the formula IV can - for instance - also be obtained by reacting a compound of the formula
  • R 6 has the meanings given for formula II, with a compound of the formula QX, wherein Q is an acidic group, preferably an inorganic acidic group, such as SO 2 X 1 ( and Xi has the meanings given for formula II, in order to obtain a compound of the formula IV, wherein n 0 ist, and - if desired - further reacting the compound of the formula IV, wherein n is 0, with an oxidizing agent, such as hydrogenperoxid, in order to obtain a compound of the formula IV, wherein n is 1 or 2.
  • the compounds of the formula VII can for instance be obtained by reacting a compound of the formula VI with a compound of the formula R 6 X 2 , wherein R 6 has the meaning as given for formula II and X 2 is a leaving group, preferably in the presence of a base.
  • the invention relates to all those embodiments of the process which are based on starting materials or intermediates obtainable from any stage of the process and in which all or some of the missing steps are carried out or in which a starting material is used or, in particular, formed under the reaction conditions in the form of a derivative or salt and/or its racemates or enantiom ⁇ rs.
  • the invention relates in particular to the processes described in Examples H1 to H8.
  • Example H2 3-(2-Benzylthiothiazol-5-ylmethyl)-5-methyl-4-nitroimino-perhvdro-1.3.5- oxadiazine (Compound No. 2.9 in Table 2)
  • Example H4 3-(2-Chlorothiazol-5-vlmethvl)-5-methyl-4-nitroimino-perhvdro-1.3.5-oxadiazine (Compound No. 11.1 in Table 11 )
  • Example H5 3-(2-Chlorothiazol-5-ylmethyl)-5-methyl-4-nitroimino-perhydro-1 ,3,5-oxadiazine (Compound No. 11.1 in Table 11 )
  • Example H6 3-(2-Chlorothiazol-5-vlmethvl)-5-methyl-4-nitroimino-perhvdro-1.3.5-oxadiazine (Compound No. 11.1 in Table 11 )
  • Example H8 Analogously to the procedures described in Examples H1 to H7, also the other compounds listed in Tables 1 to 13 can be prepared.
  • the temperatures stated in the column “Physical data” of these tables in each case denote the melting point of the respective compound; “decomp.” means decomposition.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention porte sur un procédé de préparation d'un composé répondant à la formule (I) dans laquelle X représente CH ou N et où Y représente NO2 ou CN et où Z représente CHR3, O, NR3 ou S. Dans cette formule, R1 et R2 représentent chacun, de façon indépendante, un hydrogène ou un alkyl, non substitué ou bien substitué par R4, ou peuvent représenter ensemble un pont alkylène à deux ou trois éléments ou un pont alkylène à deux ou trois éléments dans lequel un élément est remplacé par un hétéro-élément sélectionné dans le groupe constitué par NR5, O et S, R3 représente H ou un alkyl, non substitué ou bien substitué par R4, et R4 représente un groupe aryle non substitué ou substitué ou un groupe hétéroaryle tandis que R5 représente H ou un alkyl. Ce procédé consiste a) à faire réagir un composé répondant à la formule (II) avec un agent chlorant ou b1) faire tout d'abord réagir un composé répondant à la formule (IV) avec un composé répondant à la formule (V) et b2) faire réagir, à nouveau, le composé répondant à la formule (II) pouvant être obtenu de cette façon, avec ou sans isolation intermédiaire, avec un agent chlorant. L'invention a également trait à des intermédiaires utilisés dans le cadre du procédé susmentionné ainsi qu'à leur utilisation et à une technique de préparation de ces intermédiaires.
EP96939236A 1995-12-01 1996-12-02 Procede de preparation de composes de 2-chlorothiazole Expired - Lifetime EP0873326B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH341295 1995-12-01
CH3412/95 1995-12-01
CH341295 1995-12-01
PCT/IB1996/001329 WO1997020829A1 (fr) 1995-12-01 1996-12-02 Procede de preparation de composes de 2-chlorothiazole

Publications (2)

Publication Number Publication Date
EP0873326A1 true EP0873326A1 (fr) 1998-10-28
EP0873326B1 EP0873326B1 (fr) 2005-11-09

Family

ID=4255435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96939236A Expired - Lifetime EP0873326B1 (fr) 1995-12-01 1996-12-02 Procede de preparation de composes de 2-chlorothiazole

Country Status (21)

Country Link
US (1) US6211381B1 (fr)
EP (1) EP0873326B1 (fr)
JP (1) JP4142100B2 (fr)
KR (2) KR100519189B1 (fr)
CN (2) CN1083446C (fr)
AR (1) AR004984A1 (fr)
AT (1) ATE309230T1 (fr)
AU (1) AU7636896A (fr)
BR (1) BR9611666A (fr)
CA (2) CA2237348C (fr)
CZ (2) CZ301539B6 (fr)
DE (1) DE69635421T2 (fr)
DK (1) DK0873326T3 (fr)
ES (1) ES2252762T3 (fr)
HU (1) HUP9903701A3 (fr)
IL (3) IL139175A (fr)
MX (1) MX9804301A (fr)
PL (1) PL189519B1 (fr)
TW (1) TW480255B (fr)
WO (1) WO1997020829A1 (fr)
ZA (1) ZA9610046B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW240163B (en) * 1992-07-22 1995-02-11 Syngenta Participations Ag Oxadiazine derivatives
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
PL196029B1 (pl) 1996-12-19 2007-11-30 Syngenta Participations Ag Sposób wytwarzania pochodnych tiazolu, związek pośredni oraz sposób wytwarzania związku pośredniego
AU6205698A (en) 1996-12-19 1998-07-15 Novartis Ag Preparation of thiazoles
CA2420297C (fr) * 2000-08-23 2009-06-02 Syngenta Participations Ag Procede continu de preparation de chlorothizaoles pesticides
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007126043A1 (fr) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation Utilisation en tant que medicaments de derives d'un acide carboxylique porteurs de cycles thiazole
EP2065374A1 (fr) * 2007-11-30 2009-06-03 Bayer CropScience AG Dérivés de 2-(benzyl- et 1H-pyrazol-4-ylmethyl)sulfinyl-thiazole en tant qu'herbicides et régulateurs de la croissance de plantes
AU2015203829B2 (en) * 2007-11-30 2017-02-23 Bayer Intellectual Property Gmbh 2-(benzyl- and 1H-pyrazol-4-ylmethyl)sulfinyl thiazole derivatives as herbicides and plant growth regulators
JP2011193857A (ja) * 2010-03-24 2011-10-06 Sumitomo Chemical Co Ltd Ｎ−カルバモイルアミノ化合物の製造方法
GB2514927B (en) * 2014-05-28 2019-04-17 Rotam Agrochem Int Co Ltd Thiamethoxam and uses thereof
WO2016057931A1 (fr) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy
CA3053734A1 (fr) * 2017-02-26 2018-08-30 Oat Agrio Co., Ltd. Composes thiazole, et herbicide
CN107474022B (zh) * 2017-09-07 2020-06-26 连云港立本作物科技有限公司 噻唑基新烟碱化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67493T1 (de) * 1985-02-04 1991-10-15 Bayer Agrochem Kk Heterocyclische verbindungen.
DE3712307A1 (de) * 1987-04-10 1988-10-20 Bayer Ag 3-substituierte 1-(2-chlor-thiazol-5-yl-methyl)-2- nitroimino-1,3-diazacycloalkane
IE71183B1 (en) * 1988-12-27 1997-01-29 Takeda Chemical Industries Ltd Guanidine derivatives their production and insecticides
CA2044755A1 (fr) * 1990-06-18 1991-12-19 Bunji Natsume Pyrazolecarboxamide, composition acaricide et insecticide et composition fongicide utilisees en agriculture et en horticulture
IL99161A (en) * 1990-08-17 1996-11-14 Takeda Chemical Industries Ltd History of guanidine A process for their preparation and preparations from pesticides that contain them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9720829A1 *

Also Published As

Publication number Publication date
CZ295996B6 (cs) 2005-12-14
DK0873326T3 (da) 2006-03-27
IL124311A0 (en) 1998-12-06
DE69635421T2 (de) 2006-06-14
BR9611666A (pt) 1999-02-23
PL189519B1 (pl) 2005-08-31
AR004984A1 (es) 1999-04-07
ES2252762T3 (es) 2006-05-16
KR19990071739A (ko) 1999-09-27
WO1997020829A1 (fr) 1997-06-12
IL139175A0 (en) 2001-11-25
JP2000501413A (ja) 2000-02-08
AU7636896A (en) 1997-06-27
CN1327982A (zh) 2001-12-26
CA2237348A1 (fr) 1997-06-12
JP4142100B2 (ja) 2008-08-27
EP0873326B1 (fr) 2005-11-09
TW480255B (en) 2002-03-21
CN1083446C (zh) 2002-04-24
KR20040089750A (ko) 2004-10-21
HUP9903701A2 (hu) 2000-03-28
ZA9610046B (en) 1997-07-10
KR100489160B1 (ko) 2005-10-19
CZ166498A3 (cs) 1998-08-12
CZ301539B6 (cs) 2010-04-07
IL139174A0 (en) 2001-11-25
IL139175A (en) 2004-01-04
MX9804301A (es) 1998-09-30
CA2237348C (fr) 2007-08-21
ATE309230T1 (de) 2005-11-15
CA2591794A1 (fr) 1997-06-12
PL326973A1 (en) 1998-11-09
CN1203593A (zh) 1998-12-30
US6211381B1 (en) 2001-04-03
KR100519189B1 (ko) 2005-10-07
CN1219773C (zh) 2005-09-21
HUP9903701A3 (en) 2002-01-28
IL139174A (en) 2004-01-04
DE69635421D1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
EP0873326A1 (fr) Procede de preparation de composes de 2-chlorothiazole
SE456581B (sv) Mellanprodukter for framstellning av 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och -1,1-dioxider som er h 71-receptorantagonister
US20110306772A1 (en) Process for the preparation of 2-chloro-5-chloromethyl-thiazole
JP4217924B2 (ja) ３−アミノ−２−メルカプト安息香酸誘導体及びその製造方法
AU727669B2 (en) Process for the preparation of thiazole derivatives
EP0850231A1 (fr) Procede de preparation d'un compose a base de 2-chloro-5-chloromethyl-thiazole
JP5087610B2 (ja) ハロゲン化２−（３−ブテニルスルファニル）−１，３−チアゾールを製造する方法
WO1997023469A9 (fr) Procede de preparation du 2-chloro-5-chloromethyl-thiazole
EP0958286A1 (fr) Procede de preparation de derives de thiazole
CA1143739A (fr) Procede de fabrication de 5-mercapto-1,2,3-triazoles
AU2002300672B2 (en) Process for preparing 2-chlorothiazole compounds
AU2006200339B2 (en) Process for preparing 2-chlorothiazole compounds
Kaugars et al. The reactions of 5-amino-1, 2, 3, 4-thiatriazoles with isocyanates
US20240101547A1 (en) Method for preparing 2-[2-(2-chlorothiazol-5-yl)-2-oxo-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin-4-one
HU196957B (en) Process for producing o-carbamoyl-methyl-esters of n'-/acyl-hydrazine/-n-thiocarboxylic acids
CZ2000568A3 (cs) Způsob výroby substituovaných 2- nitroguanidinových derivátů
JPH01230553A (ja) 含窒素複素環四級塩及びその製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB IE IT LI NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.

Owner name: NOVARTIS AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SYNGENTA PARTICIPATIONS AG

17Q First examination report despatched

Effective date: 20021111

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB IE IT LI NL SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69635421

Country of ref document: DE

Date of ref document: 20051215

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2252762

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060810

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20101210

Year of fee payment: 15

Ref country code: AT

Payment date: 20101129

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20101218

Year of fee payment: 15

Ref country code: GB

Payment date: 20101201

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20101124

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20111213

Year of fee payment: 16

Ref country code: CH

Payment date: 20111213

Year of fee payment: 16

Ref country code: IE

Payment date: 20111212

Year of fee payment: 16

Ref country code: FR

Payment date: 20111219

Year of fee payment: 16

Ref country code: FI

Payment date: 20111212

Year of fee payment: 16

Ref country code: NL

Payment date: 20111220

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20111229

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120116

Year of fee payment: 16

BERE Be: lapsed

Owner name: *SYNGENTA PARTICIPATIONS A.G.

Effective date: 20121231

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20130701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121203

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 309230

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121202

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20121202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121202

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121231

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69635421

Country of ref document: DE

Effective date: 20130702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121202

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130702

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121202

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121231

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130102

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121203